See more : Brunswick Bancorp (BRBW) Income Statement Analysis – Financial Results
Complete financial analysis of Evercore Inc. (EVR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evercore Inc., a leading company in the Financial – Capital Markets industry within the Financial Services sector.
You may be interested
- Air T, Inc. (AIRTW) Income Statement Analysis – Financial Results
- Vext Science, Inc. (VEXT.CN) Income Statement Analysis – Financial Results
- Everdisplay Optronics (Shanghai) Co., Ltd. (688538.SS) Income Statement Analysis – Financial Results
- Canadian GoldCamps Corp. (CAMP.CN) Income Statement Analysis – Financial Results
- Fiserv, Inc. (0IP9.L) Income Statement Analysis – Financial Results
Evercore Inc. (EVR)
About Evercore Inc.
Evercore Inc., together with its subsidiaries, operates as an independent investment banking advisory firm in the United States, Europe, Latin America, and internationally. It operates through two segments, Investment Banking and Investment Management. The Investment Banking segment offers strategic advisory services, such as mergers and acquisitions, strategic, defense, and shareholder advisory, special committee assignments, and transaction structuring; Capital Markets Advisory, including equity capital markets, restructuring, debt advisory, private placement advisory, market risk management and hedging, private capital advisory, and private funds; and research, sales, and trading professionals services on a content-led platform to its institutional investor clients. The Investment Management segment provides wealth management services to high-net-worth individuals, foundations, and endowments; and manages financial assets for institutional investors. The company was formerly known as Evercore Partners Inc. and changed its name to Evercore Inc. in August 2017. Evercore Inc. was founded in 1995 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.43B | 2.76B | 3.29B | 2.26B | 2.01B | 2.06B | 1.70B | 1.44B | 1.22B | 915.86M | 765.43M | 642.37M | 524.26M | 378.90M | 313.14M | 194.66M | 321.60M | 208.00M | 125.64M | 86.32M | 60.12M |
| Cost of Revenue | 62.06M | 1.80B | 1.96B | 1.49B | 1.31B | 1.29B | 1.05B | 990.47M | 878.07M | 613.67M | 538.73M | 483.08M | 398.36M | 280.05M | 233.44M | 164.83M | 319.90M | 29.06M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.36B | 958.34M | 1.33B | 774.52M | 697.42M | 778.10M | 651.38M | 449.58M | 345.21M | 302.19M | 226.70M | 159.30M | 125.91M | 98.85M | 79.70M | 29.83M | 1.70M | 178.94M | 125.64M | 86.32M | 60.12M |
| Gross Profit Ratio | 97.44% | 34.70% | 40.32% | 34.21% | 34.72% | 37.69% | 38.22% | 31.22% | 28.22% | 33.00% | 29.62% | 24.80% | 24.02% | 26.09% | 25.45% | 15.32% | 0.53% | 86.03% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.25 | 0.34 | 0.24 | 0.22 | 0.26 | 0.25 | 0.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.66B | 1.70B | 1.85B | 1.37B | 1.20B | 1.20B | 962.51M | 900.59M | 788.18M | 549.52M | 485.79M | 430.42M | 357.68M | 251.92M | 210.82M | 146.66M | 299.33M | 72.91M | 24.12M | 17.08M | 12.45M |
| Selling & Marketing | 193.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.85B | 1.70B | 1.85B | 1.37B | 1.20B | 1.20B | 962.51M | 900.59M | 788.18M | 549.52M | 485.79M | 430.42M | 357.68M | 251.92M | 210.82M | 146.66M | 299.33M | 72.91M | 24.12M | 17.08M | 12.45M |
| Other Expenses | 0.00 | -1.98B | -4.15B | -3.16B | -2.82B | -2.86B | -1.23B | -1.15B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -83.23M | 76.00K | -37.32M |
| Operating Expenses | 1.85B | 172.77M | -2.30B | -1.79B | -1.62B | -1.55B | 65.06M | 57.67M | 50.82M | 45.43M | 36.45M | 35.51M | 33.52M | 28.46M | 20.93M | 16.17M | 28.69M | 23.89M | -59.11M | 21.32M | -24.87M |
| Cost & Expenses | 1.85B | 1.98B | -2.30B | -1.79B | -1.62B | -1.55B | 1.12B | 1.05B | 928.88M | 659.09M | 575.18M | 518.58M | 431.87M | 308.51M | 254.37M | 181.00M | 348.59M | 52.95M | -59.11M | 21.32M | -24.87M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 24.14M | 9.27M | 209.00K | 145.00K | 250.00K |
| Interest Expense | 16.72M | 16.85M | 17.59M | 21.41M | 20.14M | 17.77M | 20.00M | 16.74M | 16.98M | 15.54M | 14.01M | 15.30M | 19.39M | 22.84M | 24.27M | 30.28M | 18.45M | 8.50M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 66.50M | 2.06B | 2.18B | 1.69B | 1.56B | 1.52B | 1.25B | 1.17B | 27.93M | 16.26M | 14.54M | 16.83M | 17.75M | 10.08M | 4.52M | 4.62M | 17.42M | 4.51M | 778.00K | 667.00K | 626.00K |
| EBITDA | 445.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 219.61M | 213.48M | 158.95M | 101.12M | 74.11M | 44.93M | 45.14M | 0.00 | 0.00 | 100.36M | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 18.35% | 25.15% | 30.89% | 22.31% | 21.08% | 25.81% | 25.23% | 18.67% | 13.61% | 20.74% | 19.29% | 14.61% | 13.25% | 15.63% | 15.36% | 15.60% | 4.28% | 43.82% | 53.57% | 60.89% | 59.67% |
| Operating Income | 575.94M | 666.93M | 988.14M | 478.73M | 392.48M | 503.53M | 403.89M | 243.57M | 136.87M | 171.17M | 130.96M | 75.10M | 49.07M | 47.68M | 42.23M | 25.74M | -3.64M | 86.64M | 66.52M | 51.89M | 35.25M |
| Operating Income Ratio | 23.74% | 24.15% | 30.04% | 21.15% | 19.54% | 24.39% | 23.70% | 16.91% | 11.19% | 18.69% | 17.11% | 11.69% | 9.36% | 12.58% | 13.49% | 13.23% | -1.13% | 41.65% | 52.95% | 60.12% | 58.63% |
| Total Other Income/Expenses | -210.15M | -173.76M | -149.59M | -226.55M | -208.88M | -174.80M | -117.81M | -169.94M | -203.40M | -111.52M | -85.90M | -24.81M | -19.63M | 1.45M | -20.84M | -35.13M | -46.40M | -6.22M | 66.53M | 29.00K | -9.00K |
| Income Before Tax | 365.79M | 704.04M | 1.12B | 540.83M | 448.71M | 551.37M | 437.65M | 267.82M | 134.72M | 176.13M | 138.50M | 70.39M | 36.73M | 33.69M | 19.78M | -9.38M | -54.94M | 94.13M | 66.53M | 51.92M | 35.24M |
| Income Before Tax Ratio | 15.08% | 25.49% | 33.94% | 23.89% | 22.34% | 26.70% | 25.68% | 18.60% | 11.01% | 19.23% | 18.09% | 10.96% | 7.01% | 8.89% | 6.32% | -4.82% | -17.08% | 45.26% | 52.96% | 60.15% | 58.62% |
| Income Tax Expense | 80.57M | 172.63M | 248.03M | 128.15M | 95.05M | 108.52M | 258.44M | 119.30M | 77.03M | 68.76M | 63.69M | 30.91M | 22.72M | 15.88M | 19.53M | 179.00K | 12.40M | 8.40M | 3.37M | 2.11M | 905.00K |
| Net Income | 255.48M | 476.52M | 740.12M | 350.57M | 297.44M | 377.24M | 125.45M | 107.53M | 42.86M | 86.87M | 53.26M | 28.89M | 6.95M | 8.95M | -1.57M | -4.71M | -34.50M | 69.74M | 63.15M | 49.78M | 34.34M |
| Net Income Ratio | 10.53% | 17.25% | 22.50% | 15.49% | 14.81% | 18.27% | 7.36% | 7.47% | 3.50% | 9.49% | 6.96% | 4.50% | 1.33% | 2.36% | -0.50% | -2.42% | -10.73% | 33.53% | 50.27% | 57.67% | 57.13% |
| EPS | 6.71 | 12.15 | 18.48 | 8.64 | 7.44 | 8.33 | 3.16 | 2.74 | 1.15 | 2.42 | 1.65 | 0.98 | 0.26 | 0.45 | -0.10 | -0.36 | -3.38 | 10.97 | 15.81 | 12.46 | 8.60 |
| EPS Diluted | 6.37 | 11.61 | 17.08 | 8.23 | 6.89 | 8.33 | 2.80 | 2.43 | 0.98 | 2.08 | 1.38 | 0.89 | 0.23 | 0.39 | -0.10 | -0.36 | -3.38 | 10.97 | 15.81 | 12.46 | 8.60 |
| Weighted Avg Shares Out | 38.10M | 39.22M | 40.05M | 40.55M | 39.99M | 45.28M | 39.64M | 39.22M | 37.16M | 35.83M | 32.21M | 29.28M | 26.02M | 19.66M | 15.55M | 13.07M | 10.22M | 6.36M | 4.00M | 4.00M | 4.00M |
| Weighted Avg Shares Out (Dil) | 40.10M | 41.04M | 43.32M | 42.62M | 43.19M | 45.28M | 44.83M | 44.19M | 43.70M | 41.84M | 38.48M | 32.55M | 29.40M | 22.97M | 15.55M | 13.07M | 10.22M | 6.36M | 4.00M | 4.00M | 4.00M |
Quest Diagnostics to Speak at the 7th Annual Evercore HealthCONx Conference
SECAUCUS, N.J. , Dec. 3, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends...
Dentsply Sirona to Participate in the 7th Annual Evercore ISI HealthCONx Conference
CHARLOTTE, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 7th Annual Evercore ISI HealthCONx Conference. Management is scheduled to participate in a...
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference
HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today announced that management will participate in a...
Mapi Pharma is Seeking New Depot Product Partnerships
Management to Participate in 7th Annual Evercore HealthCONx Conference Management to Participate in 7th Annual Evercore HealthCONx Conference
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including...
TG Therapeutics to Participate in the Evercore HealthCONx Conference
Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen,...
Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference.
Evercore ISI's Mark Mahaney on why Amazon and Uber are his top two stock picks
Mark Mahaney, Evercore ISI head of internet research, joins 'Squawk Box' to discuss the latest market trends, state of internet and tech stocks, his top stock picks, and more.
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference
PHILADELPHIA , Nov. 27, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a...
Source: https://incomestatements.info
Category: Stock Reports